1. Home
  2. MDWD vs AMRN Comparison

MDWD vs AMRN Comparison

Compare MDWD & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • AMRN
  • Stock Information
  • Founded
  • MDWD 2000
  • AMRN 1989
  • Country
  • MDWD Israel
  • AMRN Ireland
  • Employees
  • MDWD N/A
  • AMRN N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • AMRN Biotechnology: Pharmaceutical Preparations
  • Sector
  • MDWD Health Care
  • AMRN Health Care
  • Exchange
  • MDWD Nasdaq
  • AMRN Nasdaq
  • Market Cap
  • MDWD 184.8M
  • AMRN 189.2M
  • IPO Year
  • MDWD 2014
  • AMRN 1993
  • Fundamental
  • Price
  • MDWD $17.64
  • AMRN $0.56
  • Analyst Decision
  • MDWD Strong Buy
  • AMRN Buy
  • Analyst Count
  • MDWD 1
  • AMRN 1
  • Target Price
  • MDWD $25.00
  • AMRN N/A
  • AVG Volume (30 Days)
  • MDWD 68.1K
  • AMRN 1.7M
  • Earning Date
  • MDWD 11-26-2024
  • AMRN 02-27-2025
  • Dividend Yield
  • MDWD N/A
  • AMRN N/A
  • EPS Growth
  • MDWD N/A
  • AMRN N/A
  • EPS
  • MDWD N/A
  • AMRN N/A
  • Revenue
  • MDWD $19,720,000.00
  • AMRN $241,021,000.00
  • Revenue This Year
  • MDWD $10.37
  • AMRN N/A
  • Revenue Next Year
  • MDWD $26.36
  • AMRN N/A
  • P/E Ratio
  • MDWD N/A
  • AMRN N/A
  • Revenue Growth
  • MDWD N/A
  • AMRN N/A
  • 52 Week Low
  • MDWD $11.04
  • AMRN $0.43
  • 52 Week High
  • MDWD $24.00
  • AMRN $1.37
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 49.76
  • AMRN 60.59
  • Support Level
  • MDWD $15.80
  • AMRN $0.43
  • Resistance Level
  • MDWD $19.60
  • AMRN $0.49
  • Average True Range (ATR)
  • MDWD 0.98
  • AMRN 0.03
  • MACD
  • MDWD 0.06
  • AMRN 0.01
  • Stochastic Oscillator
  • MDWD 48.42
  • AMRN 91.43

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About AMRN Amarin Corporation plc

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.

Share on Social Networks: